LIFSCREEN : Evaluation of Whole Body MRI for Early Detection of Cancers in Subjects With P53 Mutation (Li-Fraumeni Syndrome)

Phase 3

Completed

• Conditions: Li Fraumeni Syndrome

• Registration Number: NCT01464086
• Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Brief Summary

The purpose of this study is to compare the diagnostic efficacy of two follow-up schedules for the early detection of cancers in the population under study on cancer incidence at 3 years.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-10-27
• Study First Submitted: 2011-10-31
• Study First Submitted QC: 2011-11-02
• Study First Posted: 2011-11-03
• Primary Completion: 2017-03-31
• Study Completion: 2017-10-09
• Status Verified: 2021-02
• Last Update Submitted: 2021-02-23
• Last Update Posted: 2021-02-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 107

Inclusion Criteria

• P53 mutation

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
cancer incidence	3 years	cancer incidence during the first 3 years

Trial Locations

Locations (1)

Institut Gustave Roussy; 🇫🇷 Villejuif, France